Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.81
-0.16 (-2.68%)
At close: Mar 28, 2025, 4:00 PM
5.76
-0.05 (-0.86%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 800 employees as of December 31, 2024. The number of employees increased by 300 or 60.00% compared to the previous year.
Employees
800
Change (1Y)
300
Growth (1Y)
60.00%
Revenue / Employee
$73,549
Profits / Employee
-$579,576
Market Cap
2.34B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RXRX News
- 25 days ago - Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says - Benzinga
- 4 weeks ago - Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th - GlobeNewsWire
- 5 weeks ago - Altitude Lab Startups Raise $154M in Capital - GlobeNewsWire
- 6 weeks ago - Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off - Seeking Alpha
- 7 weeks ago - Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference - GlobeNewsWire
- 2 months ago - Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More - GlobeNewsWire